These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 24332698)

  • 1. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study).
    Lip GY; Gitt AK; Le Heuzey JY; Bash LD; Morabito CJ; Bernhardt AA; Sisk CM; Chazelle F; Crijns HJ;
    Am J Cardiol; 2014 Feb; 113(3):480-4. PubMed ID: 24332698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
    Piccini JP; Stevens SR; Lokhnygina Y; Patel MR; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Breithardt G;
    J Am Coll Cardiol; 2013 May; 61(19):1998-2006. PubMed ID: 23500298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anticoagulation and electrical cardioversion of chronic atrial fibrillation: proposal for an abbreviated protocol].
    Antonielli E; Pizzuti A; Gandolfo N; Sclavo M; Tanga M; Riva G; Leonardi G; Bassignana A; Di Leo M
    G Ital Cardiol; 1997 Aug; 27(8):803-10. PubMed ID: 9312508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
    Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
    Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Singer DE; Albers GW; Dalen JE; Go AS; Halperin JL; Manning WJ
    Chest; 2004 Sep; 126(3 Suppl):429S-456S. PubMed ID: 15383480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial.
    Apostolakis S; Haeusler KG; Oeff M; Treszl A; Andresen D; Borggrefe M; Lip GY; Meinertz T; Parade U; Samol A; Steinbeck G; Wegscheider K; Breithardt G; Kirchhof P
    Int J Cardiol; 2013 Oct; 168(4):3977-81. PubMed ID: 23871349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study.
    Crijns HJ; Weijs B; Fairley AM; Lewalter T; Maggioni AP; Martín A; Ponikowski P; Rosenqvist M; Sanders P; Scanavacca M; Bash LD; Chazelle F; Bernhardt A; Gitt AK; Lip GY; Le Heuzey JY
    Int J Cardiol; 2014 Apr; 172(3):588-94. PubMed ID: 24556445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardioversion under the guidance of transesophageal echochardiograhy in persistent atrial fibrillation: results with low molecular weight heparin.
    Akdeniz B; Türker S; Oztürk V; Badak O; Okan T; Aslan O; Kozan O; Kirimli O; Aytekin D; Bariş N; Güneri S
    Int J Cardiol; 2005 Jan; 98(1):49-55. PubMed ID: 15676166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion.
    Roijer A; Eskilsson J; Olsson B
    Eur Heart J; 2000 May; 21(10):837-47. PubMed ID: 10781356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial.
    Klein AL; Grimm RA; Jasper SE; Murray RD; Apperson-Hansen C; Lieber EA; Black IW; Davidoff R; Erbel R; Halperin JL; Orsinelli DA; Porter TR; Stoddard MF;
    Am Heart J; 2006 Feb; 151(2):380-9. PubMed ID: 16442904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Singer DE; Albers GW; Dalen JE; Fang MC; Go AS; Halperin JL; Lip GYH; Manning WJ
    Chest; 2008 Jun; 133(6 Suppl):546S-592S. PubMed ID: 18574273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new therapeutic strategy for electrical cardioversion of atrial fibrillation.
    de Luca I; Sorino M; Del Salvatore B; de Luca L
    Ital Heart J; 2001 Nov; 2(11):831-40. PubMed ID: 11770868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in anticoagulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation.
    Benetos G; Bonou M; Toutouzas K; Diamantopoulos P; Viniou N; Barbetseas J
    Hamostaseologie; 2017 Oct; 37(4):277-285. PubMed ID: 28289746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transesophageal echocardiography-guided cardioversion of atrial fibrillation. Selection of a low-risk group for immediate cardioversion.
    Fonseca N; Caetano F; Santos J; Seixo F; Bernardino L; Silvestre I; Cardoso P; Segurado F; Inês L
    Rev Port Cardiol; 2004 Mar; 23(3):365-75. PubMed ID: 15185562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.
    Femia G; Fetahovic T; Shetty P; Lee A
    Heart Lung Circ; 2018 Jul; 27(7):798-803. PubMed ID: 28802808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi.
    Manning WJ; Silverman DI; Gordon SP; Krumholz HM; Douglas PS
    N Engl J Med; 1993 Mar; 328(11):750-5. PubMed ID: 8437595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician practices regarding anticoagulation and cardioversion of atrial fibrillation.
    Schlicht JR; Davis RC; Naqi K; Cooper W; Rao BV
    Arch Intern Med; 1996 Feb; 156(3):290-4. PubMed ID: 8572839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department.
    Stiell IG; Macle L;
    Can J Cardiol; 2011; 27(1):38-46. PubMed ID: 21329861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.